Thanh Hoa Vo1,2, Edel McNeela1,2, Orla O’Donnovan1,2, Jai Prakash Mehta3, Van Hoa Nguyen4, Sweta Rani1,2,*
Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.075346
- 21 May 2026
Abstract Long non-coding RNAs (lncRNAs) have emerged as key regulators of drug resistance in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a subtype in which both intrinsic and acquired resistance to HER2-targeted therapies remain major clinical challenges. Although mechanistic studies have begun to reveal how lncRNAs modulate signaling pathways, interact with microRNAs, and influence the tumor microenvironment, dedicated investigations in HER2-positive disease are still limited. This review synthesizes current evidence across epigenetic, transcriptional, and post-transcriptional mechanisms of resistance, including competing endogenous RNA (ceRNA) networks, RNA-binding protein interactions, and exosome-mediated intercellular communication. Particular emphasis is… More >